Malaria

MPAC meeting 31 January - 2 February 2012

Declaration of Interests

All MPAC members participating in the meeting updated their declaration of interest, which was assessed by the WHO Secretariat.

Eight members reported relevant interests, which are disclosed below. It was concluded that all members could take part in full in all of the discussions, except for two members who were recused from the sessions where they had a conflict of interest. All the reported relevant interests are summarized below:

Fred Binka

• Established INESS, the Indepth Network for Effectiveness and Safety Studies, with research funding from the Bill & Melinda Gates Foundation. This interest was assessed as non-personal, non-specific, and financially significant*.

Brian Greenwood

• Received research funding from the Malaria Vaccine Initiative. This interest was assessed as non-personal, non-specific, and financially significant*. In addition, Prof. Greenwood has been a Principal Investigator on several studies of Seasonal Malaria Chemoprevention and excused himself from this discussion.

Kevin Marsh

• Directs the Kenya Medical Research Institute which receives research funding from the Wellcome Trust and Malaria Vaccine Initiative. This interest was assessed as non-personal, non-specific, and financially significant*.

Sylvia Meek

• Is technical director of the Malaria Consortium which receives research funding from the Bill & Melinda Gates Foundation. This interest was assessed as being non-personal, non-specific, and financially significant*.

Allan Schapira

• Received consultancy fees from GHTech, the Bill & Melinda Gates Foundation, World Bank, and the Swiss Tropical and Public Health Institute. This interest was assessed as being personal, non-specific, and financially significant*.

• Holds significant shares in the following companies: Novartis, Roche, Bayer, BASF, Merck, and Pfizer. This interest was assessed as being personal, specific, and financially significant*. Dr. Schapira was recused from 'Session 4: Larviciding' and asked to leave the room. He will not be involved in MPAC recommendations regarding larviciding. With regard to ¨Session 7: Seasonal Malaria Chemoprevention', he was allowed to listen to discussion, but did not participate in discussion and will not be involved in MPAC recommendations regarding Seasonal Malaria Chemoprevention.

Marcel Tanner

• Directs the Swiss Tropical and Public Health Institute which receives research funding from Novartis Institute for Tropical Diseases, SNF, Wellcome Trust, Malaria Vaccine Initiative and the Bill & Melinda Gates Foundation. This interest was assessed to be non-personal, non-specific, and financial significant*.

• Receives consultancy fees from the Novartis Institute for Tropical Diseases, which are received by the Swiss Tropical and Public Health Institute and not by Prof. Tanner. This interest was assessed to be non-personal, non-specific, and financial significant*.

Neena Valecha

• Directs the National Institute of Malaria Research - New Delhi, which receives research funding from companies: BASF, Sumitomo, Vestergaard, Bayer, and Syngata. This interest was assessed to be non-personal, specific, and financial significant*. Dr Valecha was recused from 'Session 4: Larviciding' and asked to leave the room. She will not be involved in MPAC recommendations regarding larviciding.


* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single malaria-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one malaria-related company in excess of 1,000 USD would also constitute a “significant shareholding”.

Last updated: 3 February 2012

Share